ArticleClinical lipidology2009
HDL as a contrast agent for medical imaging.
Article in Clinical lipidology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- A Synthetic Nanoparticle to Mimic High-Density Lipoprotein for Reverse Cholesterol Transport.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Nanodiscs: A toolkit for membrane protein science.Protein science : a publication of the Protein Society · 2021Review
- High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.Frontiers in cardiovascular medicine · 2020Review
- Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.Molecules (Basel, Switzerland) · 2019Review
- Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution.Nanoscale · 2017Article
- A facile method for isolation of recombinant human apolipoprotein A-I from E. coli.Protein expression and purification · 2017Article
- Immune cell screening of a nanoparticle library improves atherosclerosis therapy.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Biocompatibility of ferritin-based nanoparticles as targeted MRI contrast agents.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Molecular magnetic resonance imaging of atherosclerotic vessel wall disease.European radiology · 2016Review
- Regression of Atherosclerosis: The Journey From the Liver to the Plaque and Back.Arteriosclerosis, thrombosis, and vascular biology · 2016Review
- Nanodiscs as a Modular Platform for Multimodal MR-Optical Imaging.Bioconjugate chemistry · 2015Article
- Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics.Cholesterol · 2015Review
- Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.Current medicinal chemistry · 2015Review
- Accumulation of nano-sized particles in a murine model of angiogenesis.Biochemical and biophysical research communications · 2014Article
- Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics.ACS nano · 2013Article
- Utilizing imaging tools in lipidology: examining the potential of MRI for monitoring cholesterol therapy.Clinical lipidology · 2012Article
- Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.Nano letters · 2011Article
- Imaging of atherosclerosis.Annual review of medicine · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Contrast-enhanced MRI of atherosclerosis can provide valuable additional information on a patient's disease state. As a result of the interactions of HDL with atherosclerotic plaque and the flexibility of its reconstitution, it is a versatile candidate for the delivery of contrast-generating materials to this pathogenic lesion. We herein discuss the reports of HDL modified with gadolinium to act as an MRI contrast agent for atherosclerosis. Furthermore, HDL has been modified with fluorophores and nanocrystals, allowing it to act as a contrast agent for fluorescent imaging techniques and for computed tomography. Such modified HDL has been found to be macrophage specific, and, therefore, can provide macrophage density information via noninvasive MRI. As such, modified HDL is currently a valuable contrast agent for probing preclinical atherosclerosis. Future developments may allow the application of this particle to further diseases and pathological or physiological processes in both preclinical models as well as in patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.